Urge your members of Congress to support continued medical research funding
The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.
Blood is the official journal of the American Society of Hematology and the most cited peer-reviewed publication in the field. It is published weekly every Thursday, except for the last week in December, in addition to the ASH Annual Meeting Abstracts issue in November.
Blood Advances, the first journal to join the Blood family in 70 years, is a peer-reviewed, online only, open access journal. Under the direction of founding editor-in-chief Robert Negrin, MD, the inaugural issue made it's debut in December at the 58th ASH Annual Meeting and Exposition in San Diego.
Explore programs offered by ASH to support clinical and scientific hematology research
ASH's strategic plan highlighting the importance of placing hematology as a top funding priority in the healthcare community
Dr. Teachey reviews a study that helps expand understanding of T-cell acute lymphoblastic leukemia biology.
Dr. Jacobson looks at a study that considers therapies other than ibrutinib for mantle cell lymphoma.
Dr. Moss reviews the pathogenesis and potential eradication of favism.
Drs. Bustoros, Liu, Sklavenitis-Pistofidis, and Ghobrial look at studies by Dr. Robert Kyle that have transformed the landscape of precursor conditions is plasma cell malignancies and cancer, specifically the understanding of MGUS.
On December 20, the House of Representatives and the Senate voted to approve H.R. 1, tax reform legislation. Select members of each chamber came together to resolve disagreements between the two versions passed by the House and Senate.
Congress spent much of 2017 focused on the repeal and replace of the Affordable Care Act (ACA). Included is a summary of Congress and the Administration’s actions on repeal and replace of the ACA that occurred in 2017.
ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2017.
ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2017.
Urge your members of Congress to support continued medical research funding.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology